Roivant Sciences Ltd. (NASDAQ:ROIV) Given Average Rating of “Buy” by Brokerages

Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) have been assigned a consensus recommendation of “Buy” from the seven research firms that are currently covering the company, Marketbeat.com reports. One analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $18.08.

Several research firms have issued reports on ROIV. Cantor Fitzgerald raised shares of Roivant Sciences to a “strong-buy” rating in a research report on Thursday, January 30th. HC Wainwright reiterated a “buy” rating and issued a $18.00 price target on shares of Roivant Sciences in a report on Tuesday, February 11th.

Insider Activity

In related news, CIO Mayukh Sukhatme sold 412,584 shares of the firm’s stock in a transaction dated Wednesday, December 18th. The stock was sold at an average price of $12.05, for a total transaction of $4,971,637.20. Following the sale, the executive now owns 18,836,547 shares of the company’s stock, valued at $226,980,391.35. This trade represents a 2.14 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Sciences Ltd. Roivant bought 16,845,010 shares of Roivant Sciences stock in a transaction on Monday, January 13th. The stock was purchased at an average price of $20.00 per share, with a total value of $336,900,200.00. Following the completion of the acquisition, the director now directly owns 96,650,341 shares of the company’s stock, valued at $1,933,006,820. This represents a 21.11 % increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders sold 2,388,170 shares of company stock worth $27,612,299. 7.90% of the stock is currently owned by corporate insiders.

Institutional Trading of Roivant Sciences

Institutional investors have recently modified their holdings of the company. Russell Investments Group Ltd. lifted its position in Roivant Sciences by 478.6% during the fourth quarter. Russell Investments Group Ltd. now owns 2,355 shares of the company’s stock valued at $28,000 after acquiring an additional 1,948 shares during the last quarter. Gladius Capital Management LP acquired a new position in shares of Roivant Sciences during the third quarter worth $35,000. US Bancorp DE increased its position in shares of Roivant Sciences by 146.5% during the third quarter. US Bancorp DE now owns 3,278 shares of the company’s stock worth $38,000 after purchasing an additional 1,948 shares in the last quarter. Aster Capital Management DIFC Ltd purchased a new stake in shares of Roivant Sciences during the 4th quarter valued at $39,000. Finally, GAMMA Investing LLC boosted its position in shares of Roivant Sciences by 57.0% in the 4th quarter. GAMMA Investing LLC now owns 3,548 shares of the company’s stock worth $42,000 after purchasing an additional 1,288 shares in the last quarter. 64.76% of the stock is currently owned by institutional investors.

Roivant Sciences Stock Up 1.0 %

ROIV opened at $10.60 on Friday. The business has a fifty day moving average of $11.14 and a 200 day moving average of $11.60. Roivant Sciences has a 52-week low of $9.76 and a 52-week high of $13.06. The stock has a market cap of $7.56 billion, a P/E ratio of -70.66 and a beta of 1.25.

Roivant Sciences (NASDAQ:ROIV) last issued its earnings results on Monday, February 10th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.04. Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. Equities analysts anticipate that Roivant Sciences will post -0.92 EPS for the current fiscal year.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.